NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

$NRXPPress releaseMay 5, 2026, 7:00 AM ETRead the release

NRx Pharmaceuticals started commercial manufacturing for its preservative-free ketamine, transmitting an initial GMP order to a US partner in anticipation of GDUFA approval in Summer 2026. The product utilizes a blow-fill-seal process for over 10-fold higher throughput than traditional bottling and eliminates the toxic preservative Benzethonium Chloride.

Key figures

Throughput multiple: 10-fold
Registration batches: 3
Expected approval timing: Summer 2026

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.